West Pharmaceutical Services (WST) Non-Current Debt (2009 - 2026)

West Pharmaceutical Services has disclosed Non-Current Debt across 18 years of filings, most recently posting $202.8 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $202.8 million, changed 0.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $202.8 million (changed 0.1% YoY), and the FY2025 annual result was $202.8 million, changed 0.1% from the prior year.
• Non-Current Debt came in at $202.8 million for Q1 2026 at West Pharmaceutical Services, roughly flat from $202.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $208.3 million in Q1 2022 to a low of $72.8 million in Q4 2023.
• The 5-year median for Non-Current Debt is $202.7 million (2025), against an average of $178.3 million.
• Across the five-year window, Non-Current Debt tumbled 64.78% in 2023 and soared 178.3% in 2024, its largest moves.
• West Pharmaceutical Services' Non-Current Debt stood at $206.7 million in 2022, then sank by 64.78% to $72.8 million in 2023, then jumped by 178.3% to $202.6 million in 2024, then gained by 0.1% to $202.8 million in 2025, then changed by 0.0% to $202.8 million in 2026.
• The last three Non-Current Debt figures came in at $202.8 million (Q1 2026), $202.8 million (Q4 2025), and $202.7 million (Q3 2025), per Business Quant data.